Biologics - Initiating, Assessing, Switching, Stopping

The presentation focuses on biologics for treating atopic dermatitis, specifically discussing their initiation, assessment, switching, and stopping. It highlights the progress in treatment options for patients, emphasizing the ease of initiating biologics without the need for baseline or ongoing monitoring. Key biologics mentioned include dupilumab, trilokinumab, and the upcoming lebrikizumab, each with specific dosing regimens and efficacy metrics. Dupilumab has shown long-term efficacy data, demonstrating sustained improvement in skin clearance and itch relief. Trilokinumab is effective for patients aged 12 and up, and long-term studies indicate a majority of patients maintain significant improvement over time. The need for patient-centered assessments, including itch and sleep patterns, is underlined. The presentation also touches on the potential for switching biologics due to ocular surface disease, with some success reported in such cases. Additionally, a tapering strategy for those responding well to treatment could allow for reduced dosing intervals while maintaining control of the disease. Future biologics, particularly nemolyzumab, are anticipated to enhance treatment options further. Overall, the session conveys optimism regarding the evolving landscape of biologic therapies for atopic dermatitis.